Please confirm topic selection

Are you sure you want to trigger topic in your Anconeus AI algorithm?

Please confirm action

You are done for today with this topic.

Would you like to start learning session with this topic items scheduled for future?

Updated: Aug 17 2019


  • Snapshot
    • A 66-year-old man presents to a movements disorder specialist for management of his Parkinson disease. The patient believes that his quality of life has improved while being on carbidopa-levodopa. He is able to engage in his activities of daily living with minimal trouble. However, he notices moments of involuntary movements while being on this medication regimen, which has been troubling for him. Physical examination is notable for mild bradykinesia and an episode of short-lived myoclonus. He is started on amantadine to help reduce these dyskinesias.
  • Introduction
    • Mechanism of action
      • anti-viral effects
        • prevents the release of the viral nucleic acid into the host cell by interfering with viral M2 protein
      • anti-Parkinsonian effects
        • increases dopamine release and decreases dopamine reuptake
    • Mechanism of resistance
      • altered M2 protein
        • no longer recommended for chemoprophylaxis or treatment of influenza A infection
    • Clinical use
      • Parkinson disease
    • Adverse effects
      • ataxia
      • livedo reticularis
1 of 0
1 of 1
Private Note

Attach Treatment Poll
Treatment poll is required to gain more useful feedback from members.
Please enter Question Text
Please enter at least 2 unique options
Please enter at least 2 unique options
Please enter at least 2 unique options